It will be good to see the difference in viral load in the brilacidin vs. placebo groups to know if it helps as an antiviral.
What to make of this study showing vaccination status (yes vs. no) and symptom severity (asymptomatic vs. symptomatic) make no difference in terms of initial viral load of SARS2-delta by PCR Ct evaluation?
It could easily be interpreted to say that this thing (pandemic / virus) will go through society at its own pace, infecting both the vaccinated and unvaccinated the same way initially (though lower chance of being infected if vaccinated). I do believe vaccination will save people from severe disease, but that's about all one can say for SARS2-delta infection, at least based on this study. Would like to see more data on SARS2-delta hospitalizations and severe disease based on vaccination status. We know vaccination efficacy wanes over time, but can't say if that is due to time or the effect of vaccine not working as well against SARS2-delta vs. SARS2-Wuhan (against which the vaccine was developed).
I guess another conclusion would be that neutralizing antibodies don't always neutralize the virus or have much effect on initial infection, if viral load is the same in both vaccinated (with neutralizing ABs) and unvaccinated. Presumably neutralizing antibodies do help some ward off initial infection, but it's interesting why not all, or why those infected have the same viral load whether vaccinated or not. It would have been great to see neutralizing antibody titers versus PCR Ct at initial infection.
It's possible that the vaccinated are able to clear the same viral load faster than unvaccinated, and thus be infectious for shorter amount of time.
News 
Market Data 
Discover 
